FDA's "Holding On The Merits" Test
In the latest development relating to the triggering of the 180-day generic marketing exclusivity period, the U.S. District Court for the District of Columbia upheld the Food & Drug Administration's ("FDA")...To view the full article, register now.
Already a subscriber? Click here to view full article